WOBURN, Mass. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ) today reported financial and business highlights for the quarter ended September 30, 2019 . The Company develops and commercializes products for the chronic pain and diabetes markets that utilize neurostimulation

WOBURN, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes markets, today announced important updates to its Quell ® 2.0 commercial strategy.  This novel wearable device

WOBURN, Mass. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 third quarter financial results before the opening of the market on Thursday, October 17, 2019 . The Company will host a conference call at 8:00 a.m., Eastern Time on

WALTHAM, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ) today reported financial and business highlights for the quarter ended June 30, 2019 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and digital medicine.

WALTHAM, Mass. , July 11, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 second quarter financial results before the opening of the market on Thursday, July 18, 2019 . The Company will host a conference call at 8:00 a.m., Eastern Time on

WALTHAM, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating

WALTHAM, Mass. , May 21, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize

WALTHAM, Mass. , May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled “Transcutaneous Electrical Nerve Stimulator with automatic detection of user sleep-wake state.” The patent covers

WALTHAM, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, 2019 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and digital

WALTHAM, Mass. , April 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market on Thursday, April 25, 2019. The Company will host a conference call at 8:00 a.m., Eastern